EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Fortrea Holdings's enterprise value is €3,588 Mil.
Fortrea Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was €2,780 Mil. Therefore, Fortrea Holdings's EV-to-Revenue for today is 1.29.
The historical rank and industry rank for Fortrea Holdings's EV-to-Revenue or its related term are showing as below:
FRA:K67'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.26 Med: 1.42 Max: 1.69
Current: 1.29
During the past 4 years, the highest EV-to-Revenue of Fortrea Holdings was 1.69. The lowest was 1.26. And the median was 1.42.
FRA:K67's EV-to-Revenue is ranked better than 85.74% of 1038
companies
in the Biotechnology industry
Industry Median: 8.145
vs FRA:K67: 1.29
As of today (2024-05-27), Fortrea Holdings's stock price is €23.00.
Fortrea Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €31.27. Therefore, Fortrea Holdings's PS Ratio for today is 0.74.
Fortrea Holdings EV-to-Revenue Historical Data
The historical data trend for Fortrea Holdings's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Fortrea Holdings's EV-to-Revenue
For the Biotechnology subindustry, Fortrea Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortrea Holdings's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortrea Holdings's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Fortrea Holdings's EV-to-Revenue falls into.
Fortrea Holdings's current Enterprise Value is €3,588 Mil.
Fortrea Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,780 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings's share price for today is €23.00.
Fortrea Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €31.27.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fortrea Holdings EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Fortrea Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:K67 has been successfully added to your 